A Legacy of Excellence

In 1980, Paul M. Zoll, MD, cofounded ZOLL Medical. His seminal work in electrophysiology, internal and external defibrillation, cardioversion, and external pacing provided the foundation for the company.

Dr. Zoll was a practicing physician throughout his life, with a reputation for dedication and careful attention to his patients. Today, the company culture remains centered on new technology and improvements in care in the tradition of its namesake.

ZOLL is focused on improving patient outcomes with novel resuscitation and acute critical care technology. Through our family of products, we offer the most integrated system of resuscitation solutions, as well as complementary products and services to provide data integration and management.

Hospitals, emergency medical services (EMS), and lay people across the globe use ZOLL professional defibrillators and automated external defibrillators (AEDs) every day to treat sudden cardiac arrest. Our comprehensive product portfolio also includes the world’s only wearable defibrillator, a revolutionary automated cardiopulmonary resuscitation (CPR) device, portable ventilators, intrathoracic pressure regulation (IPR) therapy devices, and a rapid, highly efficient intravascular temperature management system for patients who require therapeutic cooling or warming.

Maximizing Innovation to Save More Lives

Since our founding, ZOLL products have embodied innovation and brought new capabilities to the market. ZOLL’s CPR technology is a perfect example. Over the last decade, the importance of high-quality CPR to resuscitation success has become clear. Through our Real CPR Help®, CPR Dashboard™, and See-Thru CPR® technologies, ZOLL gives rescuers the tools they need to “maximize the quality of CPR and save more lives,” as the American Heart Association CPR quality consensus statement calls for.  

Numbers Tell the Story

International leaders in resuscitation science are using ZOLL products to improve outcomes. When first responders in Arizona deployed Real CPR Help in combination with specialized training, the likelihood of a patient surviving cardiac arrest nearly tripled. Recently cleared by the FDA, the ResQCPRTM System has demonstrated similarly impressive results. Cardiac arrest victims treated with the ResQCPRTM System were 49% more likely to be alive one year after the event than patients treated with conventional manual CPR.
Supporting Every Link in the Chain
From early intervention to post-resuscitation care, our products are designed to work together and strengthen the Chain of Survival, regardless of whether care is delivered inside or outside the hospital. At ZOLL, we feel strongly that we also need to address an additional link—data management and analysis. If you can’t measure something, you can’t improve it. Our data offerings are unmatched. When the first call comes in, EMS systems use RescueNet® Navigator to get the crew to the scene as quickly as possible. And when the crisis has passed, RescueNet Code Review enables rescuers to see events as they occurred, providing the ECG, the vital signs, and the depth and rate of compressions for a full post-event analysis of the rescue.

Distinguished by Financial Strength and Stability
The company employs more than 4,000 employees to market products in more than 140 countries. Throughout ZOLL’s first 30 years in business, the company has had consistent management, regularly ending each fiscal year with no debt and substantial assets.

In 2012, ZOLL was acquired by Asahi Kasei Corporation, part of the Asahi Kasei Group. With operations in the material, homes, and health care business sectors, Tokyo-based Asahi Kasei has more than 30,000 employees worldwide and sales of $17 billion. As part of Asahi Kasei, ZOLL has the opportunity to expedite its ever-expanding global presence.

2002
ZOLL launches the AED Plus® with CPR-D-padz® Electrodes, which enable Real CPR Help®.

2012
AsahiKASEI
Asahi Kasei acquires ZOLL for $2.2 billion, making it the largest U.S. medical company owned by Asahi Kasei.

2014
With the acquisition of Impact Instrumentation, Inc., ZOLL now offers ventilators and other respiratory care products.

2015
FDA approves ResQCPR™ System: first CPR technology to be approved for increasing survival in adults with non-traumatic out-of-hospital cardiac arrest.

2016
The ZOLL AED 3™ was launched outside of North America.*
Reliable Partner in Acute Critical Care

Recognizing the unique challenges faced by its customers, ZOLL works to address and service their needs. From ease of use to the ability to capture performance data for quality assurance, ZOLL offers a number of ways to help customers save lives while enhancing operational efficiency. And our stringent quality control and regulatory compliance programs have enabled the company’s excellent track record in uninterrupted product delivery.

ZOLL is committed to improving the therapies available to patients in need of resuscitation or acute critical care. Through ongoing research and development, intelligent engineering, and strategic acquisitions, we have pursued this goal for more than three decades. Our 15-year commitment to the development of the LifeVest® Wearable Defibrillator is testament to our unrelenting pursuit of new technology, with a tremendous payoff—more lives saved. Worldwide, LifeVest saves more than three patients per day from sudden cardiac death.

Looking Forward

At ZOLL, we plan to continue expanding our market presence by offering best-in-class, technically superior products and by adding new capabilities, including next-generation data management systems designed to expedite and improve care.

Connect with Us

To learn more about ZOLL or to schedule a meeting to discuss how our solutions can address your specific needs, please visit us today at www.zoll.com.

*ZOLL AED 3 is not available for sale in the United States. The product has not received regulatory clearance/approval by the Food and Drug Administration.